Journal profile · ENDOCRINOLOGY & METABOLISM
Lancet Diabetes & Endocrinology
ISSN 2213-8587 · eISSN 2213-8595 · Elsevier BV · ENGLAND
Lancet Diabetes & Endocrinology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 35.94; hybrid open access; APC about USD 7,280; review about 33 days (submission to acceptance, publisher); 220 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Lancet Diabetes & Endocrinology is published by Elsevier BV and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Diabetes Management and Research, Diabetes Treatment and Management and Diabetes and associated disorders, together about 35.2% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
The Lancet Diabetes & Endocrinology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The journal is the global leader for essential original research in diabetes and endocrinology and delivers expert review and candid commentary, providing a clear, independent perspective about the clinical advances and practice-changing research shaping these fields globally.The Lancet Diabetes & Endocrinology publishes papers that reflect the rich variety of ongoing clinical research in these fields, in particular in the areas of diabetes, obesity, nutrition and metabolism, osteoporosis, adrenal disorders, bone metabolism, growth disorders, lipid disorders, neuroendocrinology, paediatric endocrinology, pituitary disorders, reproductive endocrinology, and thyroid disorders.
From the journal's Aims & Scope
Research area (LetPub): ENDOCRINOLOGY & METABOLISM
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Management and ResearchMedicine13.9%
- Diabetes Treatment and ManagementMedicine11.7%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology9.6%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine7.4%
- Pancreatic function and diabetesMedicine5.6%
- Diet and metabolism studiesMedicine4.4%
- Bariatric Surgery and OutcomesMedicine4%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Endocrinology & Metabolism | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Endocrinology & Metabolism | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Endocrinology & Metabolism | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 35.94LetPub ·
- Impact factor (publisher)
- 36.3Publisher website ·
- CiteScore 2026-06
- 64.1LetPub ·
- CiteScore (publisher)
- 64.1Publisher website ·
- SJR 2026-06
- 11.61LetPub ·
- SNIP 2026-06
- 10.69LetPub ·
- h-index
- 77LetPub ·
- h-index
- 251OpenAlex ·
- i10-index
- 1,316OpenAlex ·
- 2-year mean citedness
- 17.85OpenAlex ·
- Self-citation rate
- 1.4%LetPub ·
- Share of gold OA articles
- 18.46%LetPub ·
Volume
- Articles per year
- 69LetPub ·
Articles by year OpenAlex count · 3,134 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 136 | 28 | 190 |
| 2025 | 220 | 85 | 4,642 |
| 2024 | 202 | 73 | 5,131 |
| 2023 | 212 | 102 | 6,927 |
| 2022 | 196 | 91 | 14,375 |
| 2021 | 187 | 98 | 16,696 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed
Not usableThis publisher's "received" date is mostly when the revised manuscript arrived (26% of articles were "accepted" within 3 days), so it cannot measure review time
Figures by source
- Submission to first decision
- 22 daysPublisher website ·
- First decision after review
- 32 daysPublisher website ·
- Submission to acceptance
- 33 daysPublisher website ·
- Acceptance to publication
- 73 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 7,280 / EUR 6,810 / GBP 5,830 / JPY 902,940 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2213-8587
- Electronic ISSN
- 2213-8595
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Lancet Diabetes & Endocrinology
What CAS zone is Lancet Diabetes & Endocrinology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Lancet Diabetes & Endocrinology is in Zone 1 of Medicine, and in Zone 1 of the minor category Endocrinology & Metabolism; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Lancet Diabetes & Endocrinology?
The latest impact factor listed by LetPub is 35.94; CiteScore 64.1, h-index 251.
How long does peer review take at Lancet Diabetes & Endocrinology?
The publisher reports about 33 days (submission to acceptance). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Lancet Diabetes & Endocrinology?
According to LetPub and DOAJ records, Lancet Diabetes & Endocrinology is indexed in SCIE and Scopus.
Is Lancet Diabetes & Endocrinology open access, and what is the APC?
Lancet Diabetes & Endocrinology is a hybrid journal. For open-access publication: APC about USD 7,280.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .